• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在食蟹猴中,即使没有 CD8+ T 细胞,也可以控制亚急性 SARS-CoV-2 复制。

Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques.

机构信息

AIDS Research Center, National Institute of Infectious Diseases, Tokyo, Japan.

Institute of Medical Science, University of Tokyo, Tokyo, Japan.

出版信息

PLoS Pathog. 2021 Jul 19;17(7):e1009668. doi: 10.1371/journal.ppat.1009668. eCollection 2021 Jul.

DOI:10.1371/journal.ppat.1009668
PMID:34280241
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8321216/
Abstract

SARS-CoV-2 infection presents clinical manifestations ranging from asymptomatic to fatal respiratory failure. Despite the induction of functional SARS-CoV-2-specific CD8+ T-cell responses in convalescent individuals, the role of virus-specific CD8+ T-cell responses in the control of SARS-CoV-2 replication remains unknown. In the present study, we show that subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques. Eight macaques were intranasally inoculated with 105 or 106 TCID50 of SARS-CoV-2, and three of the eight macaques were treated with a monoclonal anti-CD8 antibody on days 5 and 7 post-infection. In these three macaques, CD8+ T cells were undetectable on day 7 and thereafter, while virus-specific CD8+ T-cell responses were induced in the remaining five untreated animals. Viral RNA was detected in nasopharyngeal swabs for 10-17 days post-infection in all macaques, and the kinetics of viral RNA levels in pharyngeal swabs and plasma neutralizing antibody titers were comparable between the anti-CD8 antibody treated and untreated animals. SARS-CoV-2 RNA was detected in the pharyngeal mucosa and/or retropharyngeal lymph node obtained at necropsy on day 21 in two of the untreated group but undetectable in all macaques treated with anti-CD8 antibody. CD8+ T-cell responses may contribute to viral control in SARS-CoV-2 infection, but our results indicate possible containment of subacute viral replication in the absence of CD8+ T cells, implying that CD8+ T-cell dysfunction may not solely lead to viral control failure.

摘要

SARS-CoV-2 感染的临床表现从无症状到致命性呼吸衰竭不等。尽管在恢复期个体中诱导了功能性 SARS-CoV-2 特异性 CD8+ T 细胞反应,但病毒特异性 CD8+ T 细胞反应在控制 SARS-CoV-2 复制中的作用尚不清楚。在本研究中,我们表明在食蟹猴中缺乏 CD8+ T 细胞可以控制亚急性 SARS-CoV-2 复制。八只食蟹猴经鼻腔接种 105 或 106TCID50 的 SARS-CoV-2,其中三只于感染后第 5 天和第 7 天用抗 CD8 单克隆抗体治疗。在这三只猴子中,CD8+ T 细胞在第 7 天及之后无法检测到,而在未治疗的其余五只动物中诱导了病毒特异性 CD8+ T 细胞反应。所有猴子在感染后 10-17 天均可从鼻咽拭子中检测到病毒 RNA,抗 CD8 抗体治疗和未治疗动物的咽拭子和血浆中和抗体滴度的病毒 RNA 水平动力学相似。在未治疗组的两只动物中,在第 21 天尸检时在咽黏膜和/或咽后淋巴结中检测到 SARS-CoV-2 RNA,但在所有用抗 CD8 抗体治疗的动物中均未检测到。CD8+ T 细胞反应可能有助于 SARS-CoV-2 感染的病毒控制,但我们的结果表明,在缺乏 CD8+ T 细胞的情况下,亚急性病毒复制可能得到控制,这意味着 CD8+ T 细胞功能障碍可能不会导致病毒控制失败。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/35ebfb27baab/ppat.1009668.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/7c8d147f9771/ppat.1009668.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/0a299e93162d/ppat.1009668.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/c88407d00c92/ppat.1009668.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/bc92b1d6933b/ppat.1009668.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/35ebfb27baab/ppat.1009668.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/7c8d147f9771/ppat.1009668.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/0a299e93162d/ppat.1009668.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/c88407d00c92/ppat.1009668.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/bc92b1d6933b/ppat.1009668.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b85a/8321216/35ebfb27baab/ppat.1009668.g005.jpg

相似文献

1
Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques.在食蟹猴中,即使没有 CD8+ T 细胞,也可以控制亚急性 SARS-CoV-2 复制。
PLoS Pathog. 2021 Jul 19;17(7):e1009668. doi: 10.1371/journal.ppat.1009668. eCollection 2021 Jul.
2
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.非中和抗体依赖的 SARS-CoV-2 控制与鼻内疫苗诱导的 CD8 T 细胞反应相关。
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
3
Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques.食蟹猴中针对 SARS-CoV-2 的中和抗体依赖和非依赖免疫应答。
Virology. 2021 Feb;554:97-105. doi: 10.1016/j.virol.2020.12.013. Epub 2020 Dec 29.
4
Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques.从急性 SARS-CoV-2 感染中恢复并在 T 细胞耗竭恒河猴中产生记忆性免疫应答。
mBio. 2021 Aug 31;12(4):e0150321. doi: 10.1128/mBio.01503-21. Epub 2021 Jul 27.
5
The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues.两种猕猴物种的 SARS-CoV-2 感染后阶段与肺部和肺外组织中持续病毒复制和病理学的迹象有关。
Viruses. 2021 Aug 23;13(8):1673. doi: 10.3390/v13081673.
6
SARS-CoV-2 Viral RNA Shedding for More Than 87 Days in an Individual With an Impaired CD8+ T Cell Response.个体的 CD8+ T 细胞反应受损时,SARS-CoV-2 病毒 RNA 可超过 87 天排出。
Front Immunol. 2021 Jan 8;11:618402. doi: 10.3389/fimmu.2020.618402. eCollection 2020.
7
COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions.反映人感染 COVID-19 病理状况的 COVID-19 食蟹猴模型。
Proc Natl Acad Sci U S A. 2021 Oct 26;118(43). doi: 10.1073/pnas.2104847118.
8
Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons and marmosets.恒河猴、狒狒和绒猴肺部对SARS-CoV-2急性感染的反应。
Nat Microbiol. 2021 Jan;6(1):73-86. doi: 10.1038/s41564-020-00841-4. Epub 2020 Dec 18.
9
Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques.早期使用两种强效中和抗体联合治疗可改善临床结局,并降低感染 SARS-CoV-2 的猕猴体内的病毒复制和肺部炎症。
PLoS Pathog. 2021 Jul 6;17(7):e1009688. doi: 10.1371/journal.ppat.1009688. eCollection 2021 Jul.
10
SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses.SARS-CoV-2 持续存在与抗原特异性 CD8 T 细胞反应有关。
EBioMedicine. 2021 Feb;64:103230. doi: 10.1016/j.ebiom.2021.103230. Epub 2021 Jan 30.

引用本文的文献

1
Post Pandemic Problem, is there an animal model suitable to investigate PASC.疫情后问题,是否存在适合研究新冠后综合征(PASC)的动物模型。
Npj Imaging. 2025 Sep 15;3(1):41. doi: 10.1038/s44303-025-00101-2.
2
Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.鼻内接种小儿副流感病毒载体 SARS-CoV-2 疫苗可保护猴子。
Cell. 2022 Dec 8;185(25):4811-4825.e17. doi: 10.1016/j.cell.2022.11.006. Epub 2022 Nov 10.
3
Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues.

本文引用的文献

1
The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.中和抗体LY-CoV555可保护非人类灵长类动物免受SARS-CoV-2感染。
Sci Transl Med. 2021 May 12;13(593). doi: 10.1126/scitranslmed.abf1906. Epub 2021 Apr 5.
2
Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19.恒河猴和食蟹猴用于 COVID-19 感染模型的比较。
Nat Commun. 2021 Feb 24;12(1):1260. doi: 10.1038/s41467-021-21389-9.
3
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.
恒河猴轻度感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)与组织中抗原特异性T细胞反应之前的病毒控制有关。
Sci Immunol. 2022 Mar 10:eabo0535. doi: 10.1126/sciimmunol.abo0535.
4
Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8 T cell responses.非中和抗体依赖的 SARS-CoV-2 控制与鼻内疫苗诱导的 CD8 T 细胞反应相关。
Cell Rep Med. 2022 Jan 19;3(2):100520. doi: 10.1016/j.xcrm.2022.100520. eCollection 2022 Feb 15.
5
Beta testing the monkey model.对猴子模型进行β测试。
Nat Immunol. 2021 Oct;22(10):1201-1203. doi: 10.1038/s41590-021-01033-w.
在 COVID-19 患者中,功能性 SARS-CoV-2 特异性 T 细胞的早期诱导与快速病毒清除和轻症疾病相关。
Cell Rep. 2021 Feb 9;34(6):108728. doi: 10.1016/j.celrep.2021.108728. Epub 2021 Jan 21.
4
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.巴尼韦单抗单药或联合埃特司韦单抗治疗轻中度 COVID-19 患者对病毒载量的影响:一项随机临床试验。
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
5
SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals.恢复期 COVID-19 个体中的 SARS-CoV-2 特异性 CD8+ T 细胞应答。
J Clin Invest. 2021 Mar 1;131(5). doi: 10.1172/JCI145476.
6
COVID-19-neutralizing antibodies predict disease severity and survival.COVID-19 中和抗体可预测疾病严重程度和存活率。
Cell. 2021 Jan 21;184(2):476-488.e11. doi: 10.1016/j.cell.2020.12.015. Epub 2020 Dec 15.
7
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.对感染后长达 8 个月的 SARS-CoV-2 进行免疫记忆评估。
Science. 2021 Feb 5;371(6529). doi: 10.1126/science.abf4063. Epub 2021 Jan 6.
8
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2,一种中和抗体鸡尾酒疗法,用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
9
Correlates of protection against SARS-CoV-2 in rhesus macaques.恒河猴中 SARS-CoV-2 保护作用的相关因素。
Nature. 2021 Feb;590(7847):630-634. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.
10
COVID19- clinical presentation and therapeutic considerations.COVID19- 临床特征和治疗考虑。
Biochem Biophys Res Commun. 2021 Jan 29;538:125-131. doi: 10.1016/j.bbrc.2020.11.021. Epub 2020 Nov 11.